Want to join the conversation?
$PFE 2Q15 PR: IBRANCE continues to be well received by oncologists treating postmenopausal women with ER /HER2- advanced breast cancer. Approx. 3,000 healthcare practitioners are already prescribing IBRANCE, which is up from 800 at the end of 1Q15. Current first-line market share in this patient population was approx. 22%, up from 10% during 1Q15.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.